Optimizing R/R CLL Treatment: Therapy Sequencing and Supportive Care Strategies - Episode 9

Navigating treatment strategies for patients with multi-refractory CLL: CAR-T, ASCT, and PI3K Inhibitors

,

Panelists discuss how various additional treatment options for relapsed/refractory chronic lymphocytic leukemia (CLL) are considered, including CAR-T cell therapy, immunomodulatory drugs like lenalidomide, chemoimmunotherapy regimens, and other emerging therapies, highlighting their potential roles in the evolving treatment landscape.

EP. 1: The Current Treatment Landscape for R/R CLL
EP. 2: Impact of Prior BTKi vs BCL2i Therapy on Treatment Decision-Making in CLL
EP. 3: Key Patient-Specific Factors Guiding Treatment Selection in CLL
EP. 4: Tailoring Treatment Approaches for Rapid vs. Slow Disease Progression in CLL
EP. 5: Assessing Resistance to First-Line BTK Inhibitor Therapy: The Emergine Role of Testing in CLL
EP. 6: Pirtobrutinib in the Management of R/R CLL: Updates from the BRUIN Trial
EP. 7: Application of Pirtobrutinib in R/R CLL: Expert Perspectives
EP. 8: Influence of TLS Risk and Patient Preferences on Treatment Selection in Relapsed/Refractory CLL
Now Viewing
EP. 9: Navigating treatment strategies for patients with multi-refractory CLL: CAR-T, ASCT, and PI3K Inhibitors
EP. 10: Sequencing and Combination Strategies with Pirtobrutinib and CAR-T Therapy in R/R CLL

Video content above is prompted by the following:

  • Briefly mention additional treatment options in R/R CLL:
    • CAR-T
    • Duvelisib
    • Idelalisib ± Rituximab
    • Lenalidomide ± Rituximab
    • FCR/BR (if no TP53 or del(17p))
    • HSCT
    • Others?

Related Content:

Insights
Sequencing and Combination Strategies with Pirtobrutinib and CAR-T Therapy in R/R CLL
The Future of Lower-Risk MDS: Closing Thoughts and Unmet Needs
Optimizing AML Care Through Academic-Community Collaboration